Claims
- 1. A method for reducing formation or progression of neoplasms associated with immunosuppressive therapy in a mammal, the method comprising treating the mammal with an effective amount of a TGF-β antagonist.
- 2. The method according to claim 1, wherein the TGF-β antagonist inhibits the activity of TGF-β1.
- 3. The method according to claim 1, wherein the TGF-β antagonist inhibits the activity of TGF-β2.
- 4. The method according to claim 1, wherein the TGF-β antagonist inhibits the activity of TGF-β3.
- 5. The method according to claim 1, wherein the TGF-β antagonist inhibits the activity of more than one isoform of TGF-β.
- 6. The method according to claim 1, wherein the TGF-β antagonist comprises a protein or polypeptide.
- 7. The method according to claim 1, wherein the TGF-β antagonist comprises an antibody directed against TGF-β.
- 8. The method according to claim 1, wherein the TGF-β antagonist comprises a TGF-β receptor or fragment thereof.
- 9. The method according to claim 1, wherein the TGF-β antagonist inhibits the activity of a TGF-β receptor.
- 10. The method according to claim 9, wherein the TGF-β receptor is TGF-β receptor type 1.
- 11. The method according to claim 9, wherein the TGF-β receptor is TGF-β receptor type 2.
- 12. The method according to claim 9, wherein the TGF-β receptor is TGF-β receptor type 3.
- 13. The method according to claim 9, wherein the TGF-β antagonist is an antibody or an antibody fragment specific for the TGF-β receptor.
- 14. The method according to claim 1, wherein the mammal is a human.
- 15. The method according to claim 1, wherein the immunosuppressive therapy comprises treatment with cyclosporine.
- 16. The method according to claim 1, wherein the immunosuppressive therapy comprises treatment with FK506.
- 17. The method according to claim 1, wherein the TGF-β antagonist is administered prior to immunosuppressive therapy.
- 18. The method according to claim 1, wherein TGF-β antagonist is administered during immunosuppressive therapy.
- 19. The method according to claim 1, wherein the TGF-β antagonist is administered after immunosuppressive therapy.
- 20. The method according to claim 1, wherein the TGF-β antagonist administration overlaps the period of immunosuppressive therapy.
- 21-35. (Cancelled).
Government Interests
[0001] This work was supported at least in part by a grant award from the National Institutes of Health. The government may have certain rights to this invention.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60181526 |
Feb 2000 |
US |
Divisions (1)
|
Number |
Date |
Country |
Parent |
09780953 |
Feb 2001 |
US |
Child |
10830647 |
Apr 2004 |
US |